ReviewFrontiers in pediatrics2025
Predictive value of biomarkers in neonatal necrotizing enterocolitis.
Review in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- When It Is Not NEC: Recognizing Mimics of Necrotizing Enterocolitis in Preterm Infants.Children (Basel, Switzerland) · 2026Review
- Local Peritoneal Cytokine Response IL-1β, IL-6, TNF-α in a Standardized Neonatal Rat Model of Necrotizing Enterocolitis.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Necrotizing enterocolitis (NEC) is an acute, life-threatening intestinal disorder in neonates, associated with notably high mortality. It is characterized by insidious and non-specific early clinical manifestations, a rapid disease progression course, and often results in long-term sequelae in affected infants, such as short bowel syndrome and neurodevelopmental impairments. The pathogenesis of NEC remains complex and not fully elucidated; thus, the screening and validation of biomarkers with high specificity, high sensitivity, and clinical applicability constitutes a core strategy to enhance the efficacy of early diagnosis and accuracy of prognostic assessment for this disease. This article aims to systematically synthesize the current clinical dilemmas in the field of NEC and the update status of relevant clinical guidelines, with a focus on reviewing the research advances of both traditional and emerging biomarkers in the contexts of NEC early diagnosis, disease staging, severity stratification, prediction of surgical intervention requirements, and prognostic evaluation. Additionally, it analyzes the consistencies and discrepancies between cutting-edge research findings and clinical guidelines, and prospects the future development direction of precision diagnosis and treatment for NEC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.